Detection of high-risk human papillomavirus using menstrual blood in women with high-grade squamous intraepithelial lesions or high-risk human papillomavirus infections: A pilot study

Banghyun Lee, Hye Yon Cho, Kum Jin Jeon, Kidong Kim, Jung Ryeol Lee, Jung Joo Moon, Jae Hong No, Yong Beom Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim Few studies have reported that human papillomavirus (HPV) tests using menstrual blood (MB) may be a convenient and effective screening modality for cervical cancer. Therefore, we aimed to investigate the efficacy of detecting high-risk (HR)-HPV from MB in women with high-grade squamous intraepithelial lesions or HR-HPV infections dependent on menstrual days. Materials and Methods In this prospective exploratory pilot study, a clinical trial was conducted in 19 women. On enrollment into the study, gynecologists collected cervical cells. On the first and second day of menstruation, MB was self-collected by patients using a sanitary pad with a filter. The distribution of HPVs from MB and the accuracy of menstrual HR-HPV tests were evaluated using HPV genotyping. The agreement rate of detecting HR-HPVs using cervical and MB samples was also investigated. Results The sensitivity, specificity, positive and negative predictive values of the MB HR-HPV test for detecting cervical intraepithelial neoplasia (CIN) 3 or worse were 87.5%, 45.5%, 53.8%, and 83.3%, respectively, during both menstrual cycle day (MCD) 1 and 2 and MCD 1 only; and 62.5%, 27.3%, 38.5%, and 50.0%, respectively, during MCD 2 only. For CIN 3 or worse, the agreement rate between positive cervical and MB HR-HPV test results was 87.5% during MCD 1 and 62.5% during MCD 2. Conclusions We demonstrated the possibility of using the MB HPV test as a screening modality for cervical cancer.

Original languageEnglish
Pages (from-to)319-324
Number of pages6
JournalJournal of Obstetrics and Gynaecology Research
Volume42
Issue number3
DOIs
StatePublished - 1 Mar 2016

Fingerprint

Papillomavirus Infections
Menstrual Cycle
Cervical Intraepithelial Neoplasia
Uterine Cervical Neoplasms
Menstruation
Squamous Intraepithelial Lesions of the Cervix
Clinical Trials
Sensitivity and Specificity

Keywords

  • cervical intraepithelial neoplasia
  • genotyping technique
  • high-grade squamous intraepithelial lesion
  • human papillomavirus
  • menstruation

Cite this

@article{b4622f79fd554f38b87829b9caf5618e,
title = "Detection of high-risk human papillomavirus using menstrual blood in women with high-grade squamous intraepithelial lesions or high-risk human papillomavirus infections: A pilot study",
abstract = "Aim Few studies have reported that human papillomavirus (HPV) tests using menstrual blood (MB) may be a convenient and effective screening modality for cervical cancer. Therefore, we aimed to investigate the efficacy of detecting high-risk (HR)-HPV from MB in women with high-grade squamous intraepithelial lesions or HR-HPV infections dependent on menstrual days. Materials and Methods In this prospective exploratory pilot study, a clinical trial was conducted in 19 women. On enrollment into the study, gynecologists collected cervical cells. On the first and second day of menstruation, MB was self-collected by patients using a sanitary pad with a filter. The distribution of HPVs from MB and the accuracy of menstrual HR-HPV tests were evaluated using HPV genotyping. The agreement rate of detecting HR-HPVs using cervical and MB samples was also investigated. Results The sensitivity, specificity, positive and negative predictive values of the MB HR-HPV test for detecting cervical intraepithelial neoplasia (CIN) 3 or worse were 87.5{\%}, 45.5{\%}, 53.8{\%}, and 83.3{\%}, respectively, during both menstrual cycle day (MCD) 1 and 2 and MCD 1 only; and 62.5{\%}, 27.3{\%}, 38.5{\%}, and 50.0{\%}, respectively, during MCD 2 only. For CIN 3 or worse, the agreement rate between positive cervical and MB HR-HPV test results was 87.5{\%} during MCD 1 and 62.5{\%} during MCD 2. Conclusions We demonstrated the possibility of using the MB HPV test as a screening modality for cervical cancer.",
keywords = "cervical intraepithelial neoplasia, genotyping technique, high-grade squamous intraepithelial lesion, human papillomavirus, menstruation",
author = "Banghyun Lee and Cho, {Hye Yon} and Jeon, {Kum Jin} and Kidong Kim and Lee, {Jung Ryeol} and Moon, {Jung Joo} and No, {Jae Hong} and Kim, {Yong Beom}",
year = "2016",
month = "3",
day = "1",
doi = "10.1111/jog.12888",
language = "English",
volume = "42",
pages = "319--324",
journal = "Journal of Obstetrics and Gynaecology Research",
issn = "1341-8076",
publisher = "Blackwell Publishing Asia",
number = "3",

}

TY - JOUR

T1 - Detection of high-risk human papillomavirus using menstrual blood in women with high-grade squamous intraepithelial lesions or high-risk human papillomavirus infections

T2 - A pilot study

AU - Lee, Banghyun

AU - Cho, Hye Yon

AU - Jeon, Kum Jin

AU - Kim, Kidong

AU - Lee, Jung Ryeol

AU - Moon, Jung Joo

AU - No, Jae Hong

AU - Kim, Yong Beom

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aim Few studies have reported that human papillomavirus (HPV) tests using menstrual blood (MB) may be a convenient and effective screening modality for cervical cancer. Therefore, we aimed to investigate the efficacy of detecting high-risk (HR)-HPV from MB in women with high-grade squamous intraepithelial lesions or HR-HPV infections dependent on menstrual days. Materials and Methods In this prospective exploratory pilot study, a clinical trial was conducted in 19 women. On enrollment into the study, gynecologists collected cervical cells. On the first and second day of menstruation, MB was self-collected by patients using a sanitary pad with a filter. The distribution of HPVs from MB and the accuracy of menstrual HR-HPV tests were evaluated using HPV genotyping. The agreement rate of detecting HR-HPVs using cervical and MB samples was also investigated. Results The sensitivity, specificity, positive and negative predictive values of the MB HR-HPV test for detecting cervical intraepithelial neoplasia (CIN) 3 or worse were 87.5%, 45.5%, 53.8%, and 83.3%, respectively, during both menstrual cycle day (MCD) 1 and 2 and MCD 1 only; and 62.5%, 27.3%, 38.5%, and 50.0%, respectively, during MCD 2 only. For CIN 3 or worse, the agreement rate between positive cervical and MB HR-HPV test results was 87.5% during MCD 1 and 62.5% during MCD 2. Conclusions We demonstrated the possibility of using the MB HPV test as a screening modality for cervical cancer.

AB - Aim Few studies have reported that human papillomavirus (HPV) tests using menstrual blood (MB) may be a convenient and effective screening modality for cervical cancer. Therefore, we aimed to investigate the efficacy of detecting high-risk (HR)-HPV from MB in women with high-grade squamous intraepithelial lesions or HR-HPV infections dependent on menstrual days. Materials and Methods In this prospective exploratory pilot study, a clinical trial was conducted in 19 women. On enrollment into the study, gynecologists collected cervical cells. On the first and second day of menstruation, MB was self-collected by patients using a sanitary pad with a filter. The distribution of HPVs from MB and the accuracy of menstrual HR-HPV tests were evaluated using HPV genotyping. The agreement rate of detecting HR-HPVs using cervical and MB samples was also investigated. Results The sensitivity, specificity, positive and negative predictive values of the MB HR-HPV test for detecting cervical intraepithelial neoplasia (CIN) 3 or worse were 87.5%, 45.5%, 53.8%, and 83.3%, respectively, during both menstrual cycle day (MCD) 1 and 2 and MCD 1 only; and 62.5%, 27.3%, 38.5%, and 50.0%, respectively, during MCD 2 only. For CIN 3 or worse, the agreement rate between positive cervical and MB HR-HPV test results was 87.5% during MCD 1 and 62.5% during MCD 2. Conclusions We demonstrated the possibility of using the MB HPV test as a screening modality for cervical cancer.

KW - cervical intraepithelial neoplasia

KW - genotyping technique

KW - high-grade squamous intraepithelial lesion

KW - human papillomavirus

KW - menstruation

UR - http://www.scopus.com/inward/record.url?scp=84959340154&partnerID=8YFLogxK

U2 - 10.1111/jog.12888

DO - 10.1111/jog.12888

M3 - Article

C2 - 26627909

AN - SCOPUS:84959340154

VL - 42

SP - 319

EP - 324

JO - Journal of Obstetrics and Gynaecology Research

JF - Journal of Obstetrics and Gynaecology Research

SN - 1341-8076

IS - 3

ER -